Literature DB >> 9473310

Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene.

E G Schuetz1, K Yasuda, K Arimori, J D Schuetz.   

Abstract

The intracellular concentration of many steroids and xenobiotics is influenced by the membrane protein P-glycoprotein (Pgp). It has been inferred that the intracellular retention of many drugs that upregulate Pgp or modulate Pgp function might also be affected by Pgp. However, the ability of Pgp to influence the translocation of these drugs needs to be established to understand Pgp's influence upon their pharmacological effect. We utilized two approaches to determine the interaction of several agents with Pgp: (a) an in vitro system, LLC-PK1 cell lines and derivative LLC cell lines stably expressing on the apical membrane either mouse mdr1a or human MDR1 Pgp grown as polarized epithelium in transwell culture to measure translocation of radiolabeled drugs; and (b) an in vivo system, mdr1a nullizygous and wild-type animals, to compare the contribution of Pgp to in vivo distribution of radiolabeled drugs. In combination these complementary approaches identified erythromycin as a drug whose intracellular retention is influenced by Pgp, while the intracellular accumulation and tissue distribution of retinoic acid and benzo(a)pyrene were unaffected by Pgp. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9473310     DOI: 10.1006/abbi.1997.0537

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  16 in total

1.  Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.

Authors:  R B Kim; C Wandel; B Leake; M Cvetkovic; M F Fromm; P J Dempsey; M M Roden; F Belas; A K Chaudhary; D M Roden; A J Wood; G R Wilkinson
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

2.  Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate.

Authors:  Thomas M Polasek; John O Miners
Journal:  Eur J Clin Pharmacol       Date:  2006-01-17       Impact factor: 2.953

3.  Hepatic disposition of fexofenadine: influence of the transport inhibitors erythromycin and dibromosulphothalein.

Authors:  R W Milne; L A Larsen; K L Jørgensen; J Bastlund; G R Stretch; A M Evans
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

Review 4.  Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport.

Authors:  Kousei Ito; Hiroshi Suzuki; Toshiharu Horie; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

5.  Membrane Assays to Characterize Interaction of Drugs with ABCB1.

Authors:  Zsolt Fekete; Zsuzsanna Rajnai; Tünde Nagy; Katalin Tauberné Jakab; Anita Kurunczi; Katalin Gémes; Krisztina Herédi-Szabó; Ferenc Fülöp; Gábor K Tóth; Maciej Czerwinski; Greg Loewen; Peter Krajcsi
Journal:  J Membr Biol       Date:  2015-04-30       Impact factor: 1.843

Review 6.  Use of in vivo animal models to assess pharmacokinetic drug-drug interactions.

Authors:  Cuyue Tang; Thomayant Prueksaritanont
Journal:  Pharm Res       Date:  2010-04-29       Impact factor: 4.200

7.  Effect of ABCC2 (MRP2) transport function on erythromycin metabolism.

Authors:  R M Franke; C S Lancaster; C J Peer; A A Gibson; A M Kosloske; S J Orwick; R H Mathijssen; W D Figg; S D Baker; A Sparreboom
Journal:  Clin Pharmacol Ther       Date:  2011-03-30       Impact factor: 6.875

8.  Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in mice.

Authors:  Xianbin Tian; Jun Li; Maciej J Zamek-Gliszczynski; Arlene S Bridges; Peijin Zhang; Nita J Patel; Thomas J Raub; Gary M Pollack; Kim L R Brouwer
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

Review 9.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

10.  Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance.

Authors:  Thomas Vanhove; Hylke de Jonge; Henriëtte de Loor; Pieter Annaert; Ulf Diczfalusy; Dirk R J Kuypers
Journal:  Br J Clin Pharmacol       Date:  2016-09-20       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.